Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)’. The study aims to demonstrate the superiority of maridebart cafraglutide over placebo in reducing body weight among adults with type 2 diabetes who are overweight or obese.
The study tests maridebart cafraglutide, an experimental drug administered subcutaneously in varying doses, against a placebo. The drug is designed to aid weight reduction in the target patient group.
This interventional study is randomized with a parallel assignment model. It employs double masking, meaning both participants and investigators are unaware of the treatment allocations, focusing primarily on treatment outcomes.
The study began on March 17, 2025, with the latest update submitted on June 25, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
The outcome of this study could significantly influence Amgen’s stock performance, as positive results may enhance investor confidence and market position, especially in the competitive diabetes treatment market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.